Kodiak Sciences Inc
KODHealthcare|Biotechnology|USA
$41.28
+1.23 (+3.07%)
Tangible Book
$1.80
Upcoming Data Readouts (2)
Feb 2027
Est. completion
P3Macular Edema Secondary to Inflammation
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
NCT06996080n=300
Apr 2027
Est. completion
P3Macular Edema Secondary to Inflammation
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
NCT06990399n=600
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.
Aug 2026
P3
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
NCT06556368